Aspirin half maximal inhibitory concentration value on platelet cyclooxygenase1 in severe type-2 diabetes mellitus is not significantly different from that of healthy individuals

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 6, 2014, Pages 629-636

  Kimura, Yukio ^a   Takano, Katsuhiro ^a   Satoh, Kaneo ^a   Aida, Kaoru ^a   Kobayashi, Tetsuro ^a   Ozaki, Yukio ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Anti platelet agents; Aspirin; Cyclooxygenase; Diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; AGED; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; MIDDLE AGED; THROMBOCYTE;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION;

EID: 84906062748     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613488934     Document Type: Article

References (37)

1. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921): 81-106.
2. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(suppl 3):234S- 264S.
3. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004; 24(11):1980-1987.
4. Cattaneo M. Resistant to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5(suppl 1):230-237.
5. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10): 1206-1218.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14): 1650-1655.
7. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006; 367(9510):606-617.
8. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemostasis. 2002;88(5): 711-715.
9. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of doserelated effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation. 2007;115(25):3156-3164.
10. Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther. 2007;5(5):969-975.
11. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med. 1998;339(4):229-234.
12. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324(7329):71-86.
13. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative group of the primary prevention project. Lancet. 2001;357(9250):89-95.
14. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the primary prevention project (PPP) trial. Diabetes Care. 2003;26(12):3264-3272.
15. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56(12):3014-3019.
16. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complicat. 2008;22(3):224-228.
17. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607): 349-360.
18. Sivenius J, Laakso M, Riekkinen P Sr, Smets P, Lowenthal A. European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke. 1992;23(6):851-854.
19. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25(20):1845-1852.
20. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Sem Thromb Hemostasis. 1993;19(2):122-128.
21. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemostasis. 1992;68(5): 577-582.
22. Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83(2):148-158.
23. Angiolillo DJ, Fernandez-Ortiz A, Bernard E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430-2435.
24. Angiolillo DJ, Bernard E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelt treatment. J Am Coll Cardiol. 2006;48(2):298-304.
25. Angiolillo DJ, Shoemaker SB, Desai B, et al. A raondomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (OPtimizing anti-platelet Therapy In diabetes MellitUS) study. Circulation. 2007;115(6):708-716.
26. Pulcinelli FM, Biasucci LM, Riondino S, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009; 30(10):1279-1286.
27. Frelinger AL 3rd, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120 (25):2586-2596.
28. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemostasis. 2006; 4(6):1271-1278.
29. Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemostasis. 2007;5(1):75-81.
30. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemostasis. 2004;2(8):1282-1291.
31. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-422.
32. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004;279(5): 3254-3264.
33. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med. 2001;345(7):494-502.
34. Bhatt DL, Fox KA, Hacke W, et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med. 2006;354(16): 1706-1717.
35. Collet JP, Cuisset T, Rangé G, et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. New Engl J Med. 2012;367(22):2100-2109.
36. Reny JL, Berdagué P, Poncet A, et al.;Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients. Circulation. 2012;125(25):3201-3210.
37. Chubb AJ, Fitzgerald DJ, Nolan KB, Moman E. The productive conformation of prostaglandin G2 at the peroxidase site of prostaglandin endoperoxide H synthase: docking, molecular dynamics, and site-directed mutagenesis studies. Biochemistry. 2006;45(3):811-820.